Rob Perez Joins Flex Pharma’s Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Flex Pharma (FLKS) Appoints New COO
September 9, 2015 10:18 AM EDTFlex Pharma (NASDAQ: FLKS) announced the appointment of Kathie Lindemann as its Chief Operating Officer, reporting to Christoph Westphal M.D., Ph.D., Flex Pharmas President, CEO and Chair.
Prior to joining Flex Pharma, Ms. Lindemann served as Chief Operating Officer at DAVIDs TEA Inc (NYSE: DTEA). Ms.... More
Flex Pharma (FLKS) Adds Former Cubist Pharma CEO Perez as Director
September 8, 2015 9:48 AM EDTFlex Pharma (NASDAQ: FLKS) announced that Robert J. Perez, former Chief Executive Officer of Cubist Pharmaceuticals, Inc., has joined its Board of Directors.
Mr. Perez joined Cubist in 2003, as Senior Vice President, Sales and Marketing and led the launch of Cubicin® (daptomycin for injection). He served as Executive Vice President and Chief Operating Officer (COO) for the company from 2007 to 2012 and President and COO from 2012 to 2014. Prior to joining Cubist, he served as Vice President of Biogen, Inc.s CNS Business Unit from 2001 to 2003, where he was responsible for commercial leadership of... More
